Chul Kim on the advances in treating lung cancer with exon 20 or mutation at DCLung24

Stephen V Liu shared on X:

“Dr. Chul Kim will discuss advances in treating lung cancer with an EGFR exon 20 or a HER2 exon 20 mutation at DCLung24. Join us Saturday, October 19th in downtown Washington, DC for this IASLC (The International Association for the Study of Lung Cancer) endorsed, one-day CME meeting!”

Additional details.
Source: Stephen V Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.

Find other posts about DCLung24 on OncoDaily.